Rexlemestrocel-L (MPC-06-ID) – Investigational Cell Therapy for Chronic Lower Back Pain

Generic Name: Rexlemestrocel-L (MPC-06-ID) | Developer: Mesoblast Limited | Indication: Chronic Discogenic Lower Back Pain

Overview

Rexlemestrocel-L (MPC-06-ID) is an investigational allogeneic (donor-derived) mesenchymal precursor cell (MPC) therapy developed by Mesoblast Limited for the treatment of chronic lower back pain due to degenerative disc disease (discogenic pain). Unlike Mesoblast’s cardiac product (MPC-150-IM), this formulation is delivered via single intradiscal injection directly into the damaged intervertebral disc, aiming to regenerate disc tissue, reduce inflammation, and provide long-term pain relief.

Key Facts

Developer: Mesoblast Limited (ASX: MSB, NASDAQ: MESO)
Product code: MPC-06-ID (Mesenchymal Precursor Cells – 6 million cells – IntraDiscal)
Cell type: Allogeneic mesenchymal precursor cells (MPCs) derived from bone marrow
Indication: Chronic lower back pain due to degenerative disc disease (discogenic pain)
Delivery: Single intradiscal injection (directly into damaged intervertebral disc)
Dose: 6 million cells per disc (single treatment)
Stage: Phase III completed; partnered with Grünenthal for Europe
Status: Regulatory pathway under evaluation (US, Europe)

Chronic Lower Back Pain Background

Epidemiology & Burden

Prevalence

Global: ~540 million people affected by lower back pain at any given time
United States: ~80 million adults with chronic lower back pain (>3 months duration)
Lifetime incidence: ~80% of adults will experience lower back pain at some point
Chronic pain: ~20% of acute lower back pain cases become chronic (>12 weeks)

Economic Impact

US healthcare costs: $100+ billion annually (direct medical costs + lost productivity)
Leading cause of disability: #1 cause of years lived with disability (YLD) globally
Work loss: Leading cause of missed work days and disability claims
Quality of life: Severe impact on physical function, mental health, sleep, employment

Degenerative Disc Disease (DDD)

What is Degenerative Disc Disease?

Definition: Age-related breakdown of intervertebral discs (cushions between vertebrae)
Anatomy:
- Nucleus pulposus: Gel-like inner core (water-rich, shock-absorbing)
- Annulus fibrosus: Tough outer ring of collagen fibers
- Endplates: Cartilage layers connecting disc to vertebrae
Degeneration process:
- Loss of water content in nucleus (disc desiccation)
- Tears in annulus fibrosus (annular fissures)
- Disc height loss (collapse)
- Inflammatory mediators released (cytokines, prostaglandins)
- Nerve ingrowth into disc (normally avascular and aneural)

Discogenic Pain

Definition: Lower back pain originating from damaged intervertebral disc (not nerve compression)
Mechanism:
- Annular tears expose nucleus to immune system → inflammation
- Inflammatory mediators (TNF-α, IL-1β, IL-6, PGE2) sensitize nerve endings
- Nerve fibers grow into damaged disc (nociceptive innervation)
- Mechanical instability from disc collapse → abnormal loading, pain
Diagnosis:
- MRI: Disc degeneration (Pfirrmann grade III-IV), annular tears, Modic changes
- Provocative discography: Injection into disc reproduces patient’s pain (controversial test)
- Exclusion: No nerve root compression (radiculopathy), spinal stenosis, or other structural causes

Current Treatment Landscape

Conservative (Non-Surgical) Treatments

Physical therapy: Exercise, stretching, core strengthening
Medications:
- NSAIDs (ibuprofen, naproxen) – anti-inflammatory, pain relief
- Acetaminophen – pain relief (limited efficacy)
- Muscle relaxants – short-term use
- Opioids – high addiction risk, limited long-term efficacy
- Antidepressants (duloxetine, amitriptyline) – chronic pain management
Interventional procedures:
- Epidural steroid injections – temporary relief (weeks to months)
- Facet joint injections – if facet arthritis contributing
- Radiofrequency ablation – nerve ablation for facet or sacroiliac joint pain
Limitations: Temporary relief; do not address underlying disc degeneration

Surgical Treatments

Spinal fusion:
- Procedure: Fuse two or more vertebrae together (eliminate motion at painful segment)
- Techniques: Anterior lumbar interbody fusion (ALIF), posterior lumbar interbody fusion (PLIF), transforaminal lumbar interbody fusion (TLIF)
- Incidence: ~500,000 spinal fusions annually (US)
- Cost: $50,000–150,000 per surgery
- Outcomes: Variable; 60–70% report improvement, but 30–40% have persistent pain or complications
- Complications: Adjacent segment disease (degeneration of neighboring discs), hardware failure, infection, nerve damage
- Recovery: 3–6 months; permanent loss of spinal mobility
Artificial disc replacement:
- Procedure: Replace damaged disc with prosthetic device (preserves motion)
- Limitations: Limited long-term data; device failure risk; not widely adopted

Unmet Need

Conservative treatments provide temporary relief but don’t address disc degeneration
Surgery (fusion) is invasive, expensive, variable outcomes, and causes adjacent segment disease
Need for disease-modifying therapy: Treatment that regenerates disc tissue, reduces inflammation, and provides durable pain relief without surgery

Rexlemestrocel-L (MPC-06-ID): Technology & Mechanism

Cell Type: Mesenchymal Precursor Cells (MPCs)

What are MPCs?

Definition: Early-stage mesenchymal stem cells with enhanced regenerative potential
Source: Bone marrow from healthy adult donors
Allogeneic: “Off-the-shelf” cells (not patient-specific); single donor → thousands of doses
Immune-privileged: Low immunogenicity; no HLA matching required
Formulation: 6 million cells suspended in injection solution (optimized for disc environment)

Delivery Method: Intradiscal Injection

Procedure

Approach: Minimally invasive, image-guided injection (fluoroscopy or CT)
Access: Needle inserted through skin into damaged intervertebral disc (usually L4-L5 or L5-S1)
Injection: 6 million cells injected directly into nucleus pulposus (center of disc)
Duration: ~30 minutes (outpatient procedure)
Anesthesia: Local anesthesia + conscious sedation
Recovery: Same-day discharge; minimal downtime (vs months for fusion surgery)

Advantages of Intradiscal Injection

✅ Targeted delivery: Cells delivered directly to site of pathology (damaged disc)
✅ Minimally invasive: Needle injection (vs open surgery)
✅ Outpatient procedure: No hospitalization required
✅ Preserves anatomy: No fusion, no hardware, no loss of spinal mobility

Mechanisms of Action

1. Disc Regeneration

Extracellular matrix (ECM) production: MPCs secrete proteoglycans, collagen, and other ECM components
Restore disc hydration: Increase water-binding capacity of nucleus pulposus (restore “cushion”)
Repair annular tears: Promote healing of damaged annulus fibrosus
Increase disc height: Restore disc height (reduce mechanical stress on vertebrae)

2. Anti-Inflammatory

Cytokine modulation: Reduce pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, PGE2)
Macrophage polarization: Shift macrophages from pro-inflammatory (M1) to pro-healing (M2) phenotype
Reduce nerve sensitization: Lower inflammatory mediators that sensitize pain receptors

3. Anti-Catabolic

Inhibit matrix degradation: Reduce activity of matrix metalloproteinases (MMPs) that break down disc tissue
Reduce apoptosis: Prevent death of remaining disc cells (chondrocytes, nucleus pulposus cells)

4. Immunomodulation

Suppress autoimmune response: Disc degeneration exposes nucleus to immune system (normally immune-privileged)
Reduce immune cell infiltration: Decrease T-cell and macrophage infiltration into disc

5. Neuroprotection

Reduce nerve ingrowth: Prevent or reverse pathological nerve fiber growth into disc
Reduce pain signaling: Lower nociceptive (pain) signals from disc

Important Note: Paracrine Effects

MPCs do not become new disc cells (chondrocytes)
Therapeutic effects mediated by secreted factors (growth factors, cytokines, extracellular vesicles)
MPCs present in disc for weeks to months, then cleared; effects persist long-term
Mechanism: “Hit and run” – cells trigger regenerative cascade, then disappear

Clinical Development

Phase II Trial

Study Design

Design: Randomized, double-blind, placebo-controlled, dose-ranging trial
Population: 100 patients with chronic discogenic lower back pain (>6 months duration)
Inclusion criteria:
- Single-level lumbar disc degeneration (Pfirrmann grade III-IV on MRI)
- Positive provocative discography (injection reproduces pain)
- Failed conservative therapy (≥6 months physical therapy, medications)
- Visual Analog Scale (VAS) pain score ≥40/100
Arms:
- 6 million cells (low dose)
- 18 million cells (high dose)
- Placebo (saline injection)
Primary endpoint: Change in VAS pain score at 12 months
Secondary endpoints: Oswestry Disability Index (ODI), quality of life, disc height on MRI

Phase II Results

Pain reduction (VAS):
- 6 million cells: -25 points (statistically significant vs placebo)
- 18 million cells: -20 points (not significantly better than 6M)
- Placebo: -10 points
Functional improvement (ODI): Significant improvement with 6M dose
Disc height: Trend toward increased disc height with 6M dose (MRI)
Safety: Well-tolerated; no serious adverse events related to cells
Conclusion: 6 million cells selected for Phase III (optimal efficacy-to-dose ratio)

Phase III Trial

Study Design

Design: Randomized, double-blind, placebo-controlled, multicenter trial
Population: 360 patients with chronic discogenic lower back pain
Inclusion criteria:
- Single-level lumbar disc degeneration (L3-S1)
- Chronic pain (>6 months)
- Failed conservative therapy (≥6 months)
- VAS pain score ≥40/100
- Positive provocative discography
Arms:
- Rexlemestrocel-L: 6 million cells (single intradiscal injection)
- Placebo: Saline injection (sham procedure)
Randomization: 2:1 (rexlemestrocel-L : placebo)
Primary endpoint: Composite responder analysis at 12 months:
- ≥20-point reduction in VAS pain score AND
- ≥15-point reduction in Oswestry Disability Index (ODI) AND
- No device-related serious adverse events AND
- No additional surgical intervention (fusion, etc.)
Secondary endpoints: VAS pain, ODI, quality of life (SF-36), disc height (MRI), safety
Follow-up: 24 months

Phase III Results (Announced 2020)

Primary Endpoint (Overall Population)

Result: Did not meet statistical significance
Responder rate:
- Rexlemestrocel-L: 37% met composite endpoint
- Placebo: 29% met composite endpoint
- Difference: 8 percentage points (p=0.13, not statistically significant at p<0.05 threshold)
Interpretation: Trial missed primary endpoint in overall population

Prespecified Subgroup Analysis: Single-Level Disc Disease

Population: Patients with single-level disc degeneration (no multi-level disease)
Responder rate:
- Rexlemestrocel-L: 47% met composite endpoint
- Placebo: 26% met composite endpoint
- Difference: 21 percentage points (p=0.006, statistically significant)
Pain reduction (VAS): -30 points (rexlemestrocel-L) vs -15 points (placebo) – clinically meaningful
Functional improvement (ODI): -20 points (rexlemestrocel-L) vs -10 points (placebo)
Durability: Benefits sustained at 24 months

Safety

Adverse events: Similar between rexlemestrocel-L and placebo groups
Procedure-related complications: Rare (discitis <1%, transient pain increase ~5%)
No serious cell-related adverse events
No increased risk of disc herniation, nerve damage, or other structural complications
Overall: Well-tolerated; favorable safety profile

Why Did Overall Population Miss Primary Endpoint?

Multi-level disease: ~40% of patients had multi-level disc degeneration (not just single level)
Dilution effect: Multi-level patients less likely to respond (pain from multiple sources; single injection insufficient)
Placebo response: Higher than expected placebo response (~29% vs ~15% anticipated)
Composite endpoint: Stringent (required meeting all 4 criteria); some patients improved on pain but not function, or vice versa

Regulatory Status & Partnership

Grünenthal Partnership (2021)

Deal Overview

Partner: Grünenthal GmbH (German pharmaceutical company specializing in pain management)
Announcement: June 2021
Territory: Exclusive license for Europe, Latin America, Middle East, select Asian markets
Mesoblast retains: United States, Canada, Australia, Japan, China rights

Financial Terms

Upfront payment: US$25 million
Regulatory milestones: Up to US$235 million
Commercial milestones: Up to US$1.43 billion (sales-based)
Total potential: US$1.7 billion (milestones)
Royalties: Double-digit percentage on net sales (10–20% estimated)

Responsibilities

Grünenthal:
- Regulatory submissions and approvals (Europe, Latin America, etc.)
- Manufacturing (technology transfer from Mesoblast)
- Commercialization (marketing, sales, distribution)
- May conduct additional clinical trials if required by regulators
Mesoblast:
- Technology transfer and manufacturing support
- Clinical data package and regulatory documentation
- Ongoing R&D support

Regulatory Path Forward

Europe (Grünenthal)

Strategy: Pursue approval in single-level disc disease subgroup (positive Phase III results)
Regulatory pathway:
- EMA (European Medicines Agency) submission
- May require additional data or confirmatory trial (subgroup analysis less compelling than overall population success)
- Advanced Therapy Medicinal Product (ATMP) designation (cell therapy regulatory framework)
Timeline: Uncertain; Grünenthal evaluating regulatory strategy (2024+)
Precedent: EMA has approved therapies based on subgroup analyses in some cases (e.g., oncology)

United States (Mesoblast)

Status: No BLA submitted; Mesoblast evaluating options
Challenges:
- Primary endpoint not met in overall population
- FDA typically skeptical of subgroup analyses (post-hoc vs prespecified)
- May require additional Phase III trial in single-level disc disease population
Options:
- Option 1: Submit BLA based on single-level subgroup data; request approval with restricted indication
- Option 2: Conduct new Phase III trial enrolling only single-level patients (confirm subgroup findings)
- Option 3: Deprioritize US program; focus on Europe (Grünenthal) and other indications (heart failure)
Current status (2024): Mesoblast prioritizing heart failure (DREAM-HF) and aGVHD (remestemcel-L); back pain on hold

Other Markets

Australia: Mesoblast retains rights; TGA (Therapeutic Goods Administration) approval pathway TBD
Japan: Mesoblast retains rights; PMDA (Pharmaceuticals and Medical Devices Agency) pathway TBD
China: Mesoblast retains rights; NMPA (National Medical Products Administration) pathway TBD

Market Opportunity

Target Population

United States

Chronic lower back pain: ~80 million adults
Discogenic pain: ~40 million (50% of chronic LBP)
Single-level disc disease: ~20–25 million (subset with isolated single-level degeneration)
Failed conservative therapy: ~10–15 million (candidates for intervention)
Realistic addressable market: ~2–5 million patients (subset willing to undergo injection, no contraindications)

Europe

Chronic lower back pain: ~100 million adults
Addressable market (single-level, failed conservative therapy): ~3–6 million

Global

Chronic lower back pain: ~540 million
Addressable market (developed countries with healthcare infrastructure): ~10–20 million

Pricing & Revenue Potential

Pricing Considerations

Comparators:
- Spinal fusion surgery: $50,000–150,000 (surgery + hospitalization + recovery)
- Epidural steroid injections: $1,000–3,000 per injection (temporary relief; multiple injections needed)
- Radiofrequency ablation: $5,000–15,000 (temporary relief; 6–12 months)
- Chronic pain medications: $2,000–10,000 annually (ongoing cost)
Value proposition: One-time treatment that provides durable pain relief without surgery
Estimated pricing: $10,000–30,000 per injection (one-time)
Rationale: Cost-effective vs surgery ($50,000–150,000); durable vs injections ($1,000–3,000 × multiple)

Peak Sales Potential

United States (if approved)

Conservative scenario:
- Addressable market: 2 million patients
- Market penetration: 5% (100,000 patients treated annually at steady state)
- Price: $15,000 per treatment
- Annual revenue: $1.5 billion
Optimistic scenario:
- Addressable market: 5 million patients
- Market penetration: 10% (500,000 patients treated annually)
- Price: $20,000 per treatment
- Annual revenue: $10 billion
Analyst consensus: $500M–2B peak sales (US) if approved

Europe (Grünenthal Territory)

Addressable market: 3–6 million patients
Pricing: Lower than US ($5,000–15,000 per treatment; European price controls)
Peak sales potential: $500M–1.5B annually (Europe + Latin America + Middle East)

Global Peak Sales Potential

Total (US + Grünenthal territories + other markets): $1–3 billion peak sales (if approved globally)
Timeline to peak: 5–7 years post-approval (gradual adoption, physician training)

Reimbursement Considerations

United States

Medicare/Medicaid: Coverage uncertain
- Chronic pain treatments often scrutinized (cost containment)
- Would need to demonstrate cost-effectiveness vs surgery and conservative care
- May require prior authorization (failed conservative therapy, specific MRI criteria)
Private insurance: Coverage likely with restrictions
- Criteria: Failed ≥6 months conservative therapy, single-level disease, positive discography
- May require pre-authorization and specialist referral
Workers’ compensation: Likely covered (occupational back injuries common)

Europe

Health technology assessment (HTA): Required in most countries
Cost-effectiveness: Must demonstrate QALY benefit and reduced long-term costs vs surgery
Pricing: Negotiated country-by-country; lower than US

Challenges

Elective procedure: Not life-threatening; payers may view as “quality of life” rather than medically necessary
Alternative treatments: Surgery (fusion) already covered; payers may prefer established option
Long-term data: Need to demonstrate durability (5–10 years) to justify one-time cost

Competitive Landscape

Current Standard of Care

Conservative Treatments

Physical therapy, NSAIDs, opioids: Low cost but limited efficacy for chronic discogenic pain
Epidural injections: Temporary relief (weeks to months); requires repeated injections
Radiofrequency ablation: Temporary relief (6–12 months); not specific to disc pain

Surgical Treatments

Spinal fusion: Gold standard for severe discogenic pain; 60–70% success rate but invasive, expensive, complications
Artificial disc replacement: Limited adoption; device failure risk

Investigational Disc Regeneration Therapies

Cell Therapies

Rexlemestrocel-L (Mesoblast): Most advanced allogeneic cell therapy (Phase III completed)
Autologous disc cell therapy: Patient’s own disc cells expanded and re-injected (NuVasive/Intrexon) – Phase II trials; limited data
Adipose-derived stem cells: Multiple small companies; early-stage trials

Biologics

Growth factors (BMP, GDF-5): Injected into disc to stimulate regeneration; early-stage trials; mixed results
Platelet-rich plasma (PRP): Autologous blood product; weak evidence; not FDA-approved for disc disease

Biomaterials

Hydrogels, scaffolds: Injectable materials to restore disc height and hydration; preclinical/early clinical

Rexlemestrocel-L Competitive Advantages

✅ Most advanced: Only allogeneic cell therapy with completed Phase III trial for disc disease
✅ Allogeneic (off-the-shelf): Scalable, consistent quality vs autologous therapies
✅ Positive subgroup data: 47% responder rate in single-level disease (vs 26% placebo)
✅ Grünenthal partnership: Validates commercial potential; $1.7B milestone potential
✅ Minimally invasive: Single injection vs surgery

Challenges

❌ Primary endpoint miss: Overall population did not meet statistical significance (regulatory hurdle)
❌ Subgroup reliance: Efficacy demonstrated only in subgroup (less compelling to regulators)
❌ Competition from surgery: Spinal fusion established, covered by insurance

Investment Considerations

For Mesoblast Shareholders

Bull Case 🐂

✅ Large market opportunity: $1–3B peak sales potential (chronic back pain affects millions)
✅ Grünenthal partnership: $1.7B milestone potential + double-digit royalties; validates commercial viability
✅ Positive subgroup data: 47% responder rate in single-level disease (clinically meaningful)
✅ Unmet need: No disease-modifying therapy for discogenic pain; surgery invasive and variable outcomes
✅ Minimally invasive: Single injection vs months of recovery from fusion surgery
✅ Durable benefit: Effects sustained at 24 months (long-term pain relief)
✅ De-risked by partnership: Grünenthal funding European development/commercialization

Bear Case 🐻

❌ Primary endpoint miss: Phase III did not meet statistical significance in overall population
❌ Subgroup analysis: Regulators skeptical of post-hoc subgroups; may require new trial
❌ Regulatory uncertainty: Approval path unclear (US, Europe); may need additional data
❌ Reimbursement challenges: Elective procedure; payers may resist coverage
❌ Competition from surgery: Spinal fusion established; physicians may prefer familiar option
❌ Adoption barriers: Requires physician training, patient selection, imaging expertise
❌ Mesoblast prioritization: Company focusing on heart failure (DREAM-HF) and aGVHD; back pain lower priority
❌ Financial stress: Mesoblast burning cash; back pain program may be shelved if other programs fail

Key Catalysts

Near-Term (2024–2025)

Grünenthal regulatory updates: EMA submission, regulatory strategy announcements
Mesoblast US decision: Whether to pursue FDA approval or conduct new trial
DREAM-HF data: Heart failure trial results will determine Mesoblast’s financial viability and ability to fund back pain program

Medium-Term (2026–2028)

European approval: If Grünenthal successful with EMA (2026–2027)
Commercial launch (Europe): Revenue ramp, physician adoption
US approval: If Mesoblast pursues (2027+, if new trial conducted)

Valuation Impact

Scenario Analysis (Contribution to Mesoblast Market Cap)

European approval (base case): +$500M–1B to market cap (Grünenthal milestones + royalties)
US + Europe approval (bull case): +$2–4B to market cap (direct US sales + European royalties)
No approval (bear case): $0 (program shelved; sunk cost)

Risk-Adjusted NPV

Probability of European approval: 30–50% (subgroup analysis, regulatory uncertainty)
Probability of US approval: 10–30% (lower; may require new trial)
Peak sales (if approved): $500M–2B (Europe + US)
Risk-adjusted value: $200–500M (probability-weighted)

Key Takeaways

✅ Large unmet need: 80 million Americans with chronic lower back pain; limited effective treatments
✅ Novel regenerative approach: First allogeneic cell therapy for discogenic pain (if approved)
✅ Positive subgroup data: 47% responder rate in single-level disc disease (Phase III)
✅ Grünenthal partnership: $1.7B milestone potential; validates commercial viability
✅ Minimally invasive: Single injection vs invasive fusion surgery
❌ Primary endpoint miss: Phase III did not meet statistical significance in overall population
❌ Regulatory uncertainty: Subgroup analysis less compelling; may require additional trial
❌ Reimbursement challenges: Elective procedure; payers may resist coverage
❌ Lower priority for Mesoblast: Company focusing on heart failure and aGVHD programs
⏳ Grünenthal execution: European approval path will determine commercial viability

Related Terms

Degenerative disc disease (DDD) – Age-related breakdown of intervertebral discs
Discogenic pain – Lower back pain originating from damaged disc (not nerve compression)
Intradiscal injection – Injection directly into intervertebral disc
Mesenchymal precursor cells (MPCs) – Early-stage mesenchymal stem cells
Provocative discography – Diagnostic test injecting contrast into disc to reproduce pain
Spinal fusion – Surgical procedure fusing vertebrae together (eliminates motion)
Visual Analog Scale (VAS) – Pain assessment tool (0–100 scale)
Oswestry Disability Index (ODI) – Functional assessment for lower back pain
Grünenthal – German pharmaceutical company partnered with Mesoblast for Europe
Allogeneic cell therapy – Donor-derived cells (off-the-shelf)

Disclaimer: This information is for educational purposes only and does not constitute medical or investment advice. Rexlemestrocel-L (MPC-06-ID) is investigational; not approved for any indication. Mesoblast stock is high-risk, speculative investment with significant risks including regulatory rejection, reimbursement challenges, and financial distress. DYOR and consult professionals before making medical or investment decisions.

Mesoblast Investor Relations: investorcentre.mesoblast.com

Grünenthal: www.grunenthal.com

Clinical Trials: ClinicalTrials.gov (Search: Mesoblast, chronic lower back pain)

Related Topics: Rexlemestrocel-L, MPC-06-ID, Chronic Lower Back Pain, Degenerative Disc Disease, Discogenic Pain, Mesenchymal Stem Cells, Cell Therapy, Regenerative Medicine, Mesoblast, Grünenthal, Spinal Fusion, Intradiscal Injection, Pain Management